RELSYMPLA
LIVE

Serial Number

99862049

Owner

Veloxis Pharmaceuticals, Inc.

Attorney

Julia Anne Matheson

Filing Date

Jun 3, 2026

Add to watchlist:

No watchlists yet
View on USPTO

RELSYMPLA Trademark

Serial Number: 99862049

RELSYMPLA is a trademark filed by Veloxis Pharmaceuticals, Inc. on June 3, 2026. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Veloxis Pharmaceuticals, Inc. (12 trademarks)

2000 Regency Parkway,

Entity Type: 99

Trademark Details

Filing Date

June 3, 2026

Registration Date

Not Registered

Goods & Services

Pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of physical ailments; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of for skin wounds; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of for the treatment of burns; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of cardiovascular disease and cerebrovascular disease; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of neurological disease; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of cancer; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of osteoporosis; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of infectious diseases; pharmaceutical, peptide, and biologic preparations for the treatment of rheumatism; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of fever blisters; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of autoimmune diseases; pharmaceutical, peptide, and biologic preparations for the treatment of inflammation immunology; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of organ transplant; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of pain; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of rare diseases; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of digestive diseases; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of hematologic disorders; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of kidney diseases; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of disease with immunosuppression; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in urology; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in rheumatology; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in nephrology; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in organ transplant; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in hematology; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in orthopedic medicine; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in pulmonology; drug delivery agents in the form of solutions, compounds, powders, and tablets that facilitate delivery of a wide range of pharmaceuticals, peptides, and biologics

Filing History

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 3, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Jun 3, 2026 MAFR
NEW APPLICATION ENTERED
Jun 3, 2026 NWAP